Aligos Therapeutics, Inc. Share Price
NASDAQ: ALGS | Micro CapAligos Therapeutics, Inc. Stock Performance
Open $6.96 | Prev. Close $7.07 | Circuit Range N/A |
Day Range $6.93 - $6.96 | Year Range $4.01 - $13.58 | Volume 588 |
Average Traded $6.95 |
Aligos Therapeutics, Inc. Share Price Today
As of 29 August 2026, Aligos Therapeutics, Inc.'s share price is $6.84. The stock opened at $6.96, compared to its previous close of $7.07. During today's trading session, Aligos Therapeutics, Inc.'s share price traded between $6.93 and $6.96, with an average price of $6.95. Over the past 52 weeks, the stock has recorded a high of $13.58 and a low of $4.01. In terms of performance, Aligos Therapeutics, Inc.'s share price has declined by 1.30% over the last six months and is down 34.04% on a year-on-year basis.
Aligos Therapeutics, Inc. Share Price Chart
Aligos Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $67.61M | PE Ratio (TTM) -2.79 | Dividend Yield N/A |
EPS (TTM) $-2.45 | Revenue (TTM) $2.19M | Return On Equity (TTM) -45.18% |
Profit Margin -1106.72% | Debt to Equity 0.40 | Quarterly Earnings Growth YoY -63.75% |
Aligos Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Aligos Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Aligos Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $4.21 | $7.07 | +65.77% |
Jul 2026 | $5.65 | $4.26 | -25.63% |
Jun 2026 | $5.52 | $5.74 | +0.26% |
May 2026 | $6.16 | $5.72 | -5.61% |
Apr 2026 | $7.84 | $6.06 | -14.35% |
Mar 2026 | $6.73 | $7.08 | +2.09% |
Feb 2026 | $7.96 | $6.93 | -14.54% |
Jan 2026 | $9.21 | $8.11 | -13.92% |
Dec 2025 | $9.60 | $9.42 | -2.79% |
Nov 2025 | $7.76 | $9.69 | +16.54% |
Oct 2025 | $10.17 | $8.31 | -14.10% |
Sep 2025 | $10.79 | $9.68 | -6.65% |
ALGS Share Price FAQs
What is Aligos Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Aligos Therapeutics, Inc. stock?
What is ALGS's market capitalisation today?
What is ALGS's net income for the last quarter?
What is the 5 year returns of ALGS?
What is the high & low stock price of ALGS today?
Can I buy ALGS shares in India?